243 related articles for article (PubMed ID: 25806243)
21. The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib.
Patil T; Smith DE; Bunn PA; Aisner DL; Le AT; Hancock M; Purcell WT; Bowles DW; Camidge DR; Doebele RC
J Thorac Oncol; 2018 Nov; 13(11):1717-1726. PubMed ID: 29981925
[TBL] [Abstract][Full Text] [Related]
22. The pathological spectrum of solid CNS metastases in the pediatric population.
Wiens AL; Hattab EM
J Neurosurg Pediatr; 2014 Aug; 14(2):129-35. PubMed ID: 24926970
[TBL] [Abstract][Full Text] [Related]
23. Management of CNS disease in ALK-positive non-small cell lung cancer: Is whole brain radiotherapy still needed?
Wrona A
Cancer Radiother; 2019 Sep; 23(5):432-438. PubMed ID: 31331844
[TBL] [Abstract][Full Text] [Related]
24. Survival of breast cancer patients with synchronous or metachronous central nervous system metastases.
Ho VK; Gijtenbeek JM; Brandsma D; Beerepoot LV; Sonke GS; van der Heiden-van der Loo M
Eur J Cancer; 2015 Nov; 51(17):2508-16. PubMed ID: 26277099
[TBL] [Abstract][Full Text] [Related]
25. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
26. Dissection of the Process of Brain Metastasis Reveals Targets and Mechanisms for Molecular-based Intervention.
Weidle UH; Birzele F; Kollmorgen G; Rüger R
Cancer Genomics Proteomics; 2016; 13(4):245-58. PubMed ID: 27365375
[TBL] [Abstract][Full Text] [Related]
27. AKR1B10 (Aldo-keto reductase family 1 B10) promotes brain metastasis of lung cancer cells in a multi-organ microfluidic chip model.
Liu W; Song J; Du X; Zhou Y; Li Y; Li R; Lyu L; He Y; Hao J; Ben J; Wang W; Shi H; Wang Q
Acta Biomater; 2019 Jun; 91():195-208. PubMed ID: 31034948
[TBL] [Abstract][Full Text] [Related]
28. Platinum sensitivity and CD133 expression as risk and prognostic predictors of central nervous system metastases in patients with epithelial ovarian cancer.
Liu BL; Liu SJ; Baskys A; Cheng H; Han Y; Xie C; Song H; Li J; Xin XY
BMC Cancer; 2014 Nov; 14():829. PubMed ID: 25399490
[TBL] [Abstract][Full Text] [Related]
29. Targeting angiogenesis for treatment of NSCLC brain metastases.
Schettino C; Bareschino MA; Rossi A; Maione P; Sacco PC; Colantuoni G; Rossi E; Gridelli C
Curr Cancer Drug Targets; 2012 Mar; 12(3):289-99. PubMed ID: 22229249
[TBL] [Abstract][Full Text] [Related]
30. Central nervous system-specific efficacy of CDK4/6 inhibitors in randomized controlled trials for metastatic breast cancer.
Nguyen LV; Searle K; Jerzak KJ
Oncotarget; 2019 Oct; 10(59):6317-6322. PubMed ID: 31695840
[No Abstract] [Full Text] [Related]
31. An individual patient data meta-analysis on characteristics, treatments and outcomes of glioblastoma/ gliosarcoma patients with metastases outside of the central nervous system.
Pietschmann S; von Bueren AO; Kerber MJ; Baumert BG; Kortmann RD; Müller K
PLoS One; 2015; 10(4):e0121592. PubMed ID: 25860797
[TBL] [Abstract][Full Text] [Related]
32. Reactive Astrocytes in Brain Metastasis.
Wasilewski D; Priego N; Fustero-Torre C; Valiente M
Front Oncol; 2017; 7():298. PubMed ID: 29312881
[TBL] [Abstract][Full Text] [Related]
33. Management of CNS metastases in patients with EGFR mutation-positive NSCLC.
Shetty V; Babu S
Indian J Cancer; 2019 Nov; 56(Supplement):S31-S37. PubMed ID: 31793440
[TBL] [Abstract][Full Text] [Related]
34. A Brief Report of the Status of Central Nervous System Metastasis Enrollment Criteria for Advanced Non-Small Cell Lung Cancer Clinical Trials: A Review of the ClinicalTrials.gov Trial Registry.
McCoach CE; Berge EM; Lu X; Barón AE; Camidge DR
J Thorac Oncol; 2016 Mar; 11(3):407-13. PubMed ID: 26725180
[TBL] [Abstract][Full Text] [Related]
35. Central nervous system metastases in breast cancer.
Kiricuta IC; Kölbl O; Willner J; Bohndorf W
J Cancer Res Clin Oncol; 1992; 118(7):542-6. PubMed ID: 1624546
[TBL] [Abstract][Full Text] [Related]
36. State of the art of chemotherapy for the treatment of central nervous system metastases from non-small cell lung cancer.
Inno A; Di Noia V; D'Argento E; Modena A; Gori S
Transl Lung Cancer Res; 2016 Dec; 5(6):599-609. PubMed ID: 28149755
[TBL] [Abstract][Full Text] [Related]
37. Extracranial Abscopal Effects Induced by Brain Radiation in Advanced Lung Cancer.
D'Andrea MA; Reddy GK
Am J Clin Oncol; 2019 Dec; 42(12):951-957. PubMed ID: 31693511
[TBL] [Abstract][Full Text] [Related]
38. Predictive molecular markers in metastases to the central nervous system: recent advances and future avenues.
Berghoff AS; Bartsch R; Wöhrer A; Streubel B; Birner P; Kros JM; Brastianos PK; von Deimling A; Preusser M
Acta Neuropathol; 2014 Dec; 128(6):879-91. PubMed ID: 25287912
[TBL] [Abstract][Full Text] [Related]
39. Breast cancer metastasis to the central nervous system.
Weil RJ; Palmieri DC; Bronder JL; Stark AM; Steeg PS
Am J Pathol; 2005 Oct; 167(4):913-20. PubMed ID: 16192626
[TBL] [Abstract][Full Text] [Related]
40. Primary breast cancer phenotypes associated with propensity for central nervous system metastases.
Tham YL; Sexton K; Kramer R; Hilsenbeck S; Elledge R
Cancer; 2006 Aug; 107(4):696-704. PubMed ID: 16826579
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
